BIOMARIN PHARMACEUTICAL INC

BIOMARIN PHARMACEUTICAL INC (BMRN) is a US-listed equity tracked across major market indices. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

The company reports trailing twelve-month revenue of $373.45M and net income of $105.53M. Key metrics include a return on equity of 1.7%, a debt-to-equity ratio of 0.38.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for BMRN to support both active traders and long-term investors.